Canada markets closed

BioNTech SE (BNTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
161.62-5.09 (-3.05%)
At close: 04:00PM EST
160.90 -0.72 (-0.45%)
After hours: 05:18PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close166.71
Bid158.50 x 1100
Ask161.52 x 800
Day's Range158.36 - 166.00
52 Week Range117.08 - 312.96
Avg. Volume888,392
Market Cap39.936B
Beta (5Y Monthly)0.16
PE Ratio (TTM)3.92
EPS (TTM)41.23
Earnings DateNov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJun 02, 2022
1y Target Est215.61
  • Zacks

    Pfizer (PFE) Seeks FDA Nod for Bivalent COVID Jab in Infants

    Pfizer (PFE) and partner BioNTech seek label expansion to use their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in young children under five years.

  • Reuters

    UPDATE 1-Britain's health regulator backs COVID vaccine for infants from six months

    Britain's health regulator on Tuesday authorised a COVID-19 vaccine for infants as young as six months, opening the door for vaccinating the country's youngest children once the UK's Joint Committee on Vaccination and Immunisation (JCVI) agrees. The Medicines and Healthcare products Regulatory Agency (MHRA) authorised the vaccine - made by Pfizer and BioNTech - for children aged six months to four years old, after it was deemed safe and effective based on an ongoing clinical trial involving 4,526 participants. Whether the vaccine is eventually deployed in this age group depends on a recommendation from the JCVI, which advises UK health departments on which shots should be used as part of the national vaccination programme.

  • Reuters

    UPDATE 2-Pfizer, BioNTech countersue Moderna over COVID-19 vaccine patents

    Pfizer Inc and its German partner, BioNTech SE, fired back at Moderna Inc on Monday in a patent lawsuit over their rival COVID-19 vaccines, seeking dismissal of the lawsuit in Boston federal court and an order that Moderna's patents are invalid and not infringed. Moderna first sued Pfizer in August, accusing the company of violating its rights in three patents related to innovations that Cambridge, Massachusetts-based Moderna said it pioneered before the COVID-19 pandemic. Moderna has also filed a related lawsuit against Pfizer and BioNTech in Germany.